By Connor Hart
Theratechnologies said Thursday that patients will encounter a shortage of Egrifta SV--its prescription medicine that reduces excess belly fat in adults with HIV and lipodystrophy--in mid-January.
The Canadian biopharmaceutical company attributed the shortage to a voluntary shutdown of the drug's contract-manufacturing facility last year.
It added that it has two recently-manufactured batches of Egrifta SV waiting to be released to pharmacies. The company, however, is awaiting a response from the Food and Drug Administration regarding a prior approval supplement it submitted in December.
A prior approval supplement is a request to the FDA for approval to make a major change to a drug or biological product, and it is required before the change can be implemented and the drug can be distributed.
"We remain committed to people with HIV who rely on Egrifta SV, as it is the only FDA-approved medicine of its kind," Chief Medical Officer Christian Marsolais said. "We will continue to work with the FDA to expedite the release of the new batches for patients."
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 09, 2025 17:34 ET (22:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。